Learn about Bayer-sponsored activities at ESC Congress 2021:
Inform yourself, follow up & access the content!
Industry Q&A Symposium | Session number: 2000
Evolving cardiovascular risk: Your patient’s past, present and future
Saturday, 28 August, 13:00–13:45 CEST
Faculty: Manesh Patel, Roxana Mehran, Craig Coleman, Reinhold, Kreutz, Rónán Collins
The session highlighted the dynamic risk of thrombotic events in patients with atrial fibrillation and showed how different patient risk factors affect optimal treatment choice. Furthermore, the importance of continuous benefit-risk assessment was demonstrated to ensure patients receive the best possible protection.
Agenda
13:00-13:10
Introduction to our patient
Manesh Patel and Roxana Mehran
13:10-13:20
Patients with atrial fibrillation and diabetes
Manesh Patel and Craig Coleman
13:20-13:30
Consider the kidney: New data on patients with atrial fibrillation and renal impairment
Manesh Patel and Reinhold Kreutz
13:30-13:35
Maintaining protection: Longitudinal benefit–risk assessment in older patients
Manesh Patel and Rónán Collins
13:35-13:45
Live Q&A
Manesh Patel, Craig Coleman and Reinhold Kreutz
Exclusive Live Symposium | Session number: 2001
New therapies for patients following a worsening HF event
Saturday, 28 August, 15:00-15:30 CEST
Faculty: Paul Armstrong, Carolyn Lam, Burkert Pieske, Michele Senni
The symposium discussed the high event rates and unmet need in patients following a worsening HF event. The clinical benefits of vericiguat in this patient population and its potential role in the current treatment landscape have been reviewed by the faculty.
Agenda
15:00-15:05
Welcome and introduction
Paul Armstrong (Co-chair) (Edmonton, CA)
15:05-15:12
Therapeutic advances: A new sGC stimulator for patients following a worsening HF event
Burkert Pieske (Berlin, DE)
15:12-15:17
Top tips for practical patient management
Michele Senni (Bergamo, IT)
15:17-15:27
Live Q&A
Carolyn Lam, Paul Armstrong, Michele Senni, Burkert Pieske
15:27-15:30
Summary and close
Carolyn Lam (Co-chair) (Singapore)
Industry Q&A Symposium | Session number: 2002
What's next for your patients following a worsening HF event?
Sunday, 29 August 2021, 13:00 - 13:45 CEST
Faculty: Carolyn Lam, Faiez Zannad, Javed Butler, Ewa Jankowska
The Q&A symposium is highlighted the unmet need in patients with worsening HF and the poor prognosis following a worsening HF event. The key outcomes from the VICTORIA trial and their impact on clinical practice was reviewed and clinical decision-making for the treatment of patients after a worsening HF event has been discussed.
Agenda
13:00-13:10
Welcome and introduction
Carolyn Lam (Co-chair) (Singapore)
13:10-13:20
VICTORIA in context: Deep dive into the latest data
Javed Butler (Mississippi, US)
13:20-13:35
Live panel discussion: Managing the patient after a worsening HF event
Carolyn Lam, Javed Butler, Faiez Zannad (Nancy, FR), Ewa Jankowska (Wrocław, PL)
13:35-13:40
Live Q&A
All
13:40-13:45
Summary and close
Faiez Zannad (Co-chair)
Exclusive Live Symposium | Session number: 2003
Exploring the cardiorenal benefits of MR antagonism in CKD and T2D
Sunday, 29 August 2021, 16:50 - 17:20 CEST
Faculty: Stefan Anker, Michele Senni, Gerasimos Filippatos
The faculty described the impact of Mineralocorticoide Receptor Overactivation on cardiorenal morbidity in patients with CKD and T2D and recognised the need for novel treatments for the management of CKD in patients with T2D, including those that target MR overactivation. The symposium helped to understand how nonsteroidal MRAs can improve cardiorenal outcomes in patients with CKD in T2D.
Agenda
16:50-16:52
Welcome and introductions
Stefan Anker (Berlin, DE)
16:52-17:00
How to improve cardiorenal outcomes in patients with CKD and T2D?
Michele Senni (Bergamo, IT)
17:00-17:15
Insights into the cardiovascular and kidney benefits of MR antagonism: Insights from the FIGARO-DKD and FIDELIO-DKD trials
Gerasimos Filippatos (Athens, GR)
17:15-17:20
Live Q&A
Stefan Anker (Berlin, DE)
17:20
Summary and close
Stefan Anker (Berlin, DE)
Click here and follow our twitter channel for all updates around vascular health, venous thrombosis, atrial fibrillation and stroke prevention.
PP-FINE-ALL-0182-1
Updated date: 05/08/2021
Copyright © Bayer AG |
- PP-FINE-ALL-0182-1
Updated date 14/12/2021
La finalidad de este sitio web es proporcionar información al público
internacional fuera de los EE. UU. y el Reino Unido.
